Top 50 Biotech Startup Investors in May 2026

Portfolio highlights

• MixRift — MIXRIFT - game developers specialized in Mixed Reality
• unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
• Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Portfolio highlights

• SciNeuro — Courage Drives Change - We follow the science to deliver therapeutic solutions for CNS diseases
• Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.

Portfolio highlights

• Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
• Microtide Biotechnology — Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine.
• Sparrow Pharmaceuticals — Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess.

Portfolio highlights

• Tr1x — Tr1x develops cellular therapies intended for the treatment of autoimmune disorders.
• Proxima — Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach.Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches.
• NILO Therapeutics — A neuronal circuit regulates the immune system. We're targeting it to treat autoimmune and inflammatory diseases.

Portfolio highlights

• NodThera — NodThera is a biotechnology company treating chronic diseases by targeting inflammation at its source.
• Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
• T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .

Portfolio highlights

• Precirix — Developing radio-immunotherapeutic drugs for cancer patients.
• IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
• Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.

Portfolio highlights

• Immutrin — Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils.
• Truthsystems — Truth Systems offers real-time compliance agents that prevent human error by embedding behavioral guardrails into AI interactions.
• Bluebird Kids Health — Bluebird Kids Health is launching a proprietary technology platform to proactively manage and coordinate treatment, with AI enhancing and simplifying the experience for its clinical team.

Portfolio highlights

• Achaogen — Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrumefficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.
• Standard BioTools — Standard BioTools delivers leading genomic and proteomic solutions. Discover CyTOF, Hyperion and Biomark technologies for deep biological insights.
• Rennovia — Get full access to this domain. Easy, seamless transactions. Zero percent financing available.

Portfolio highlights

• iMile — iMile is a logistics and courier services provider across the Middle East. It is the first courier company providing smart logistics and courier services to the e-Commerce business and brings the unique value of solving Cash On Delivery (COD). iMile offers a wide range of services like Cash on Delivery with tracking, Real-Time online tracking, 24hours Customer support through Email, Chat, Social Media, SMS, International Transport, Overseas warehouses, and last-mile delivery.
• Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
• Microtide Biotechnology — Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine.

Portfolio highlights

• Disc Medicine — Committed to turning scientific discoveries into effective medicines that will disrupt the current standard of care, alleviate suffering, and have a meaningful impact on the lives of patients and their families.
• Accent Therapeutics — Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth anddifferentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.
• Caldera Therapeutics — Caldera Therapeutics is a biotech company developing bispecific antibodies like CLD-423 for IBD and inflammatory diseases. Discover innovative autoimmune treatments today.

Portfolio highlights

• Moximed — Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis.
• Gossamer Bio — Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focuson areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
• Sagimet Biosciences — Sagimet Biosciences better reflects our expertise in fatty acid metabolism and current focus on developing ground-breaking therapeutics to treat the liver disease NASH.

Portfolio highlights

• Capacity Bio — Capacity Bio is a private, biotech company developing a first-in-class mitophagy therapeutic platform, along with the most advanced analytical toolkit to characterize mitochondria.
• Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
• Avalanche Energy — Avalanche Energy operates as a fusion energy start-up.

Portfolio highlights

• Liberate Bio — Liberate Bio focuses on advancing non-viral delivery technologies for nucleic acid cargoes such as ASOs and siRNAs. The company aims to develop new vehicles to deliver oligonucleotide cargos, addressing genetic disorders. With a team of 50 employees, Liberate Bio operates within the biotechnology industry, working on innovative solutions fortargeted delivery systems.
• Li Industries — At Li Industries, we are building battery recycling technologies that enable greater automation, competitiveness, and sustainability.
• LanzaTech — LanzaTech is turning our global carbon crisis into a feedstock opportunity with the potential to displace 30% of crude oil use today and reduce global CO2 emissions by 10%. By recycling carbon from industrial off-gases; syngas generated from any biomass resource (e.g. municipal solid waste (MSW), organic industrial waste, agricultural waste); andreformed biogas, LanzaTech can reduce emissions and make new products for a circular carbon economy.LanzaTech’s carbon recycling technology is like retrofitting a brewery onto an emission source like a steel mill or a landfill site, but instead of using sugars and yeast to make beer, pollution is converted by bacteria to fuels and chemicals! Imagine a day when your plane is powered by recycled GHG emissions, when your yoga pants started life as pollution from a steel mill. This future is possible using LanzaTech technology.

Portfolio highlights

• Gamevestor — Be more than a player. Invest in expert-selected video game projects and earn a share of their commercial revenues.
• IsentroniQ — Isentroniq solves the critical cryogenic power and space bottleneck in quantum computing. Our dense, near-heatless wiring solution unlocks 1000x more qubits.
• SWEETECH — SWEETECH is a deeptech startup that specializes in the biosynthesizing of rare sugars (oligosaccharides) using a patented, eco-friendly fermentation platform. Born from a passion for biotechnology and sustainable chemistry.

Portfolio highlights

• Thirty Madison — Thirty Madison is a human-first healthcare company, powering access to affordable specialized healthcare through brands like Keeps and Cove.
• Sonrai Security — Secure cloud and enterprise privileged access with IAM solutions and identity security tools that protect users and data while helping teams deploy faster. Request a demo today.
• Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.

Portfolio highlights

• Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
• Syndax Pharmaceuticals — Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
• Portola Pharmaceuticals — As Alexion, AstraZeneca Rare Disease, we are delivering life-changing therapies to people living with rare diseases.

Portfolio highlights

• Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
• NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
• Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.

Portfolio highlights

• Ensoma — Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
• Mendra — Mendra is a biopharmaceutical company that uses AI to accelerate clinical development and commercialization of breakthrough medicines for diseases with high unmet need.
• Kinaset Therapeutics — Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.

Portfolio highlights

• Akili Interactive Labs — Akili Interactive is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine.
• NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
• Scipio Bioscience — Scipio Bioscience, a Paris-based biotechnology company, provides a novel sample preparation solutionfor single-cell studies, in the form of benchtop kits, for use in sequencing applications in clinical and basic research, in particular transcriptomics.

Portfolio highlights

• CorTec — Reliable products for active implantable device development. We realize your next project with you and offer individual solutions that meet your specific requirements for Medical Devices, especially in neurotechnology.
• Senodis — The digital transformation of industry is not developed on paper; it requires pioneering work to implement specific solutions and applications off the beaten track. With our experience and our network at the interface between materials research, optical sensors, and digital data analysis, we and our partners provide the missing building blocks forthe connection and digitization of your production.
• CenterPoint - Connective Software Engineering — CenterPoint was founded in 2000 and is based in Villach, Austria with an additional office in Warsaw, Poland. CenterPoint - Connective Software Engineering develops and markets process control and fault detection and classification software solutions. The company offers cause effect analysis, metrology assessment, and close loop and run to runcontrol services. It's focus are the semiconductors, electronics, and steel and alloy industries.

Portfolio highlights

• HerdDogg — HerdDogg is passionate about livestock. Its innovative data platform sits at the intersection of agtech, the internet of things, and global food security. Our patented DoggTags and DoggBone, together with our Animal Traceability Platform, help producers make more money from every animal they raise. The HerdDogg system enables animal tracking,welfare monitoring and traceability in an easy-to-use application. For more information, visit herddogg.com.
• Rescue Forensics — Customer service is our #1 priority. Get a premium domain for your website today. Financing available.
• Soiltech Wireless — Soiltech Wireless is a developer of ag-tech solutions to design electronic devices for agricultural professionals. Its product provides real-time data to drive efficiency and optimize quality. It also provides actionable data without installation hassles and creates scalable monitoring solutions for farmers.The company was founded in 2019 and isheadquartered in Rupert, Idaho.

Portfolio highlights

• Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
• Jounce Therapeutics — Concentra is a biosciences company.
• Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.

Portfolio highlights

• MFX — MFX is a platform designed to accelerate the development and manufacturing of cell and gene therapies.
• Aquark Technologies — Aquark Technologies develops atom systems to develop quantum applications, including atomic clocks, sensors, and navigation systems. Aquark develops a technique to miniaturize cold atom systems using unique laser geometry that is based on more than 10 years of proprietary research at the University of Southampton.
• Productive Machines — Productive Machines Chatter-free Milling Software Optimization Service for every Machine Shop. Apply our recommended spindle speeds and feed rates to your specific machine settings and make the best part, faster, right first time.

Portfolio highlights

• MarqVision — Effortlessly discover and remove counterfeits to protect your sales and reputation.
• Midas — Midas is the first neobroker of Turkey, providing zero commission Turkish and American stocks.
• Yunzhou Zhiwei — Yunzhou Zhiwei is a high-tech startup focused on serving large-scale equipment maintenance industries such as aviation, aerospace, shipbuilding, and rail transit. It leverages smart maintenance concepts and advanced digital technologies to make complex equipment maintenance more efficient and lean. The company drives industrial transformationtoward intelligent maintenance, helping enterprises enhance growth, efficiency, and operational excellence.

Portfolio highlights

• Pulnovo Medical — Pulnovo Medical integrates development, production and services. Our core products including use pf radiofrequency ablation technology to treat pulmonary hypertension. The high-frequency ablation equipment and intravascular catheters developed by the company are pioneer inventions with global invention patents.
• LYNK Pharmaceuticals — LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.
• Excalipoint Therapetics — Excalipoint Therapeutics is a Private limited company.

Portfolio highlights

• Revolut — Join 40+ million customers globally using Revolut to send money to 160+ countries, hold up-to 36 currencies in app, spend in 150+ currencies, and manage their money.
• Platfora — Platfora’s mission is to empower customers to transform their businesses into fact-based enterprises. Platfora's Big Data Analytics Platform masks the complexity of Hadoop, making it easy for customers to understand all the facts in their business across events, actions, behaviors and time.
• Lead — Lead Bank is a community-minded, independent commercial bank with a national client base recognized for its imaginative approach to community banking.

Portfolio highlights

• CarTrade — CarTrade - Buy and Sell Used Cars in India at right price. Find New Cars, car prices, upcoming cars and images. Read latest auto news, reviews and car comparisons.
• Matrimony.com — Revolutionizing the Indian matrimonial industry with world class matchmaking and wedding planning services. Your search for the perfect match ends here!
• Journey Live — Journey is shifting the way modern companies prioritize mental health. Our proactive, inclusive tools engage every employee, every day.

Portfolio highlights

• LOLIWARE — LOLIWARE is rewriting the story of destructive packaging. By harnessing the power of seaweed to replace plastic at scale, LOLIWARE is tapping into its potential to regenerate our ocean and decarbonize our planet.
• Kolors — Kolors is a technological platform that focuses on providing intelligent intercity mobility of bus transportation in the region.
• ARRIS — Using next-gen advanced manufacturing technologies, ARRIS Composites produces smarter, lighter, stronger, and more sustainable products at scale.

Portfolio highlights

• Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
• smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
• TECregen — TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses.

Portfolio highlights

• Clarifai — Clarifai is the leading Machine Learning, Computer Vision, NLP Platform. Label, train, deploy models on one AI platform for developers & data scientists.
• Primer — Primer makes powerful mission-ready AI software designed to work in your environment, on your data. We help national security teams sift through massive unstructured data sets to find the needle in the haystack, understand and visualize their data, and act collaboratively. Our mission is to empower decisions that can be defended, and acted upon confidently.
• Atavistik Bio — Atavistik Bio is harnessing the power of protein-metabolite interactions to add a new lens to drug discovery.

Portfolio highlights

• Vercel — Vercel gives developers the frameworks, workflows, and infrastructure to build a faster, more personalized web.
• Iterative Health — Iterative Health is a healthcare technology and services company that focuses on accelerating clinical research to improve patient outcomes through innovative approaches. The company transforms gastrointestinal (GI) care by utilizing AI-driven clinical trials and diagnostics, significantly enhancing access to vital treatments.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.

Portfolio highlights

• Ablexis — Ablexis, LLC, a biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery, was founded in December 2009, based on technology principles established by its subsidiary, Aliva Biopharmaceuticals, Inc.
• Artios Pharma — Artios is a leading independent DDR Company with a strong pipeline of novel cancer therapies in development with first-in-class & best-in-class potential.
• Mirna Therapeutics — Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on theemerging field of miRNA-based therapeutics.

Portfolio highlights

• KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
• Tolerance Bio — Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergi
• Vittoria Biotherapeutics — Vittoria Biotherapeutics develops gene-edited cell therapies.  they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.

Portfolio highlights

• Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
• Spero Therapeutics — Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.
• Aileron Therapeutics — Aileron Therapeutics - ALRN-6924 - myelopreservation

Portfolio highlights

• Farcast — Unlocking satellite internet capacity through user terminal innovation
• Deepcell — Deepcell uses AI to isolate and capture cells based on morphological features for multiple research and translational applications.
• Electroflow Technologies — Electroflow Technologies Inc.: Start-up working on direct Lithium extraction and refinement from low concentration brines using renewable electricity and minimal chemicals.

Portfolio highlights

• FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
• Hepster — hepster, die Onlineversicherung, flexibel, sicher und immer 100% digital.
• BAOUW / Outdoor Organic Nutrition — A raw, healthy, and natural diet made up of energy gels, energy bars, and energy fruit purees.

Portfolio highlights

• NOVAMEAT — NOVAMEAT produces plant-based meat substitutes through advanced food printing and tissue engineering technologies. Join the #novameat movement.
• CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
• Braveheart Bio — Advancing treatments to improve outcomes and quality of life for patients with hypertrophic cardiomyopathy and related heart conditions.

Portfolio highlights

• Sanegene Bio — Sanegene Bio is currently operating in stealth mode.
• Excelsior Sciences — Excelsior Sciences develops a chemistry and AI platform for discovering and manufacturing small-molecule compounds. It uses a proprietary “smart bloccs” system, which consists of modular, machine-ready chemical building blocks, to convert small-molecule innovation into an iterative, automation-friendly workflow. Through this platform, Excelsiorenables closed-loop cycles of AI-guided synthesis, testing, and optimisation that link early-stage discovery to scalable manufacturing. The company supports projects across pharmaceuticals, materials science, and other sectors that rely on small molecules. Excelsior also maintains an internal pipeline of therapeutic candidates while working with partners to deploy its chemistry platform broadly.
• Syndeio Biosciences — Syndeio Biosciences is a clinical-stage biotechnology company focused on developing therapies to restore and enhance synaptic health in central nervous system (CNS) disorders.

Portfolio highlights

• Halter — Halter creates GPS enabled, solar powered collars for cows. The collar hardware allows farmers to use simple tablet app software to remotely set geographic boundaries for cattle, virtual fences. Farmers use Halter's system to avoid physically herding cows, maximizing farmer time and productivity.
• evonetix — evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
• Fourth Power — Fourth Power makes renewable energy an on-demand energy source through utility-scale, thermal battery technology. With the ability to provide flexible-duration energy storage, we can start small and grow with the grid to save consumers money and ensure a clean energy future.

Portfolio highlights

• Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
• Ceryx Medical — Ceryx Medical Ltd are the revolutionary business behind a unique bioelectronic technology that could change the way diseases such as heart failure are treated.
• Enhanc3D Genomics — Enhanc3D Genomics is a spinout company from Babraham Institute.

Portfolio highlights

• Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
• Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
• Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.

Portfolio highlights

• Cebix — Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy.
• Trius Therapeutics — Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections.We have successfully completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. Tedizolid is an IV and orally administeredsecond generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections.Trius is headquartered in San Diego, California. We have built a strong management team with significant development and regulatory experience. Our senior management team consists of nine individuals who collectively have been involved in the development and approval of a significant number of anti-infective drugs.
• Invitae — Invitae and Labcorp together offer advanced genetic testing that can be easily integrated into medical practices. Improve patient care with meaningful insights based on DNA.

Portfolio highlights

• Zag Bio — Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
• PHNX Materials — At PHNX Materials, we transform unusable landfilled coal ash into sustainable products. Join our journey as we leverage cutting-edge chemistry to create a cleaner planet by producing a green SCM, titanium, aluminum and rare-earth elements.
• Faeth Therapeutics — Home | Faeth

Portfolio highlights

• Atavistik Bio — Atavistik Bio is harnessing the power of protein-metabolite interactions to add a new lens to drug discovery.
• Gritstone bio — Gritstone Oncology is a clinical-stage biotech company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Its approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. GritstoneOncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. It was founded in August 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS.
• Carmot Therapeutics — Breakthrough science. One moment, one day, one person at a time.

Portfolio highlights

• Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
• Mosanna Therapeutics — Mosanna is a Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach.
• Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Portfolio highlights

• ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
• HelloBetter — HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services.
• Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.

Portfolio highlights

• Trojan Energy — Trojan Energy support the roll-out of its on-street flat and flush electric vehicle charging points, which aims to solve the issue for vehicle owners who do not have access to off-street parking.
• Cumulus Oncology — Cumulus Oncology develops anti-cancer therapies for clinical settings in areas of high unmet need. We target key pathways to improve the efficacy and outcomes of current and experimental therapies. Cumulus has the backing of a successful entrepreneur in the oncology field and is led by a team of senior professionals and industry partners fromacross the drug discovery and development sector. Together, we offer a wealth of experience and deep insights into optimum approaches for improved cancer patient outcomes.
• RAB Microfluidics — We diagnose early signs of failure in lubricated machinery and prevent equipment failure using our patented microfluidic technology and AI technology.

Portfolio highlights

• Apella Technology — Apella is an AI startup that brings modern engineering to improve surgery. It collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information and spits it out in a way that that the startup says can be interpreted by hospitals to improve operations, surgical quality, training,and even real-time decision-making.Apella was founded in 2019 and is headquartered in San Francisco, California.
• Beacon Biosignals — AI + EEG to change the way patients are treated for disorders of the brain.
• Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.

Portfolio highlights

• IFM Therapeutics — IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of thecGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis
• NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
• Scorpion Therapeutics — We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy.

Portfolio highlights

• OncoC4 — OncoC4, we are a clinical-stage biotechnology company committed to transforming cutting-edge science into breakthrough therapies.
• Primelink Bio — Primelink Bio is a Biotechnology firm that is working to to develop next generation of drug delivery systems.
• Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.